| Autor: |
Souad Assaad, Cropet C, Study TIotO, Belgadi B, Philippe Zrounba, Carbonnelle G, Stefani L, Perriere Cbdl, Debreuve A, Faucher C, Dramais D, Provencal J, Durando X, Febvey-Combes O, Jean-Yves Blay, Péron J, D. Perol, Gautier J, Pernot S, Philippe Rochigneux, Hamon M, Bourgeois Tl, Briere M, Vanjak D, Campillo-Gimenez B, Lepretre S, Chergui F, Schott R, Gachot B, Simonet-Lamm Al |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
SSRN Electronic Journal. |
| ISSN: |
1556-5068 |
| Popis: |
Background: This nationwide prospective cohort reports on the outcome of patients with cancer presenting COVID-19 symptoms with or without detectable SARS-COV2 on RT-PCR and/or specific CT-scan imaging. Methods: This prospective study was conducted in 23 Cancer Centers and hospitals. Inclusion criteria were :1) confirmed diagnosis of solid or hematologic cancer in treatment and 2) clinical symptoms of COVID-19. COVID-19 infection was defined as: 1) detectable SARS-CoV2 on RT-PCR (repeated twice if negative first) and/or specific CT-scan imaging if undocumented SARS-COV-2 on RT-PCR. The primary endpoint was death at day-28 after COVID-19 test, in patients with (COVID-19 positive group) or without (COVID-19 negative group) documented COVID-19. Findings: From March 1st 2020 to May 21st 2020, 1230 cancer patients with suspicion of COVID-19, including 1162 (94·5%) matching inclusion criteria were included. 425 (36·6%) [including 155 [13·3%] with diagnosis on CT-scan only], and 737 (63·4%) were in the COVID-19+ and COVID-19- groups respectively. Deaths within 28 days after COVID-19 diagnosis occurred in 116/425 (27·8%) of COVID-19+ patients, and in 118/737 (16·3%) of COVID-19 negative patients (p 100 mg/L vs 35/203 (17·4%) of other patients died before day 28 (p |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
